Combined Moderna flu and Covid vaccine provide better protection, study finds | Vaccines and immunization

A combined flu and coronavirus vaccine provokes a greater immune response to both diseases than when the vaccines are administered separately, a clinical trial has shown.

Moderna, the biotech company behind the Spikevax vaccine used in NHS booster programs, is testing a two-in-one shot that can also protect against flu. Initial results have shown that it may be better at protecting against them than what is used now.

The results showed that the antibody response in the participants triggered higher immune responses against flu and Covid-19 than when the vaccines were administered separately.

The company said it expected the vaccine to be widely available next year.

The results come from a phase 3 randomized controlled trial involving 8,000 people divided into two groups.

The first group was 65 years old or older and was testing the new vaccine against the flu vaccine and the Spikevax vaccine, while the second group consisted of adults ages 50 to 64.

Stéphane Bancel, CEO of Moderna, said: “Combination vaccines have the potential to reduce the burden of respiratory viruses on health systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide greater protection against seasonal diseases. .

He added: “Moderna is the only company with a positive phase 3 combined flu and Covid vaccine. Building on the momentum of positive Phase 3 data across our respiratory portfolio, we continue to address important unmet medical needs and advance public health.”

Earlier this year, Boots said the retailer would offer the Pfizer-BioNTech vaccine to healthy customers in England aged 12 and over from next week, at a cost of £98.95 per jab.

Leave a Comment